Fatigue on a GLP-1 Microdose: Why Energy Dips Happen and What the Evidence Says About Fixing Them
About one in nine people on semaglutide 2.4 mg report fatigue, roughly double the placebo rate. Most of that tiredness is not the drug acting on the brain. It is the body reacting to a deficit that arrived faster than it could adapt to, and the fix depends on which part of that deficit is doing the damage.
11%
OF ADULTS ON SEMAGLUTIDE 2.4 MG REPORTED FATIGUE IN THE POOLED WEGOVY TRIALS, AGAINST 5% ON PLACEBO
35%
REDUCTION IN AD LIBITUM ENERGY INTAKE ON SEMAGLUTIDE 2.4 MG IN THE FRIEDRICHSEN 2021 STUDY
40%
OF WEIGHT LOST IN THE STEP 1 BODY COMPOSITION SUBSTUDY CAME FROM LEAN MASS RATHER THAN FAT
Three weeks into a protocol, a woman who used to run before work finds herself sitting on the edge of the bed at 6:40 am, not nauseous, not unwell, simply without the fuel to stand up and go. Her appetite is gone, which was the point. Her energy went with it, which was not.
Fatigue on a GLP-1 receptor agonist is common enough to appear in the prescribing information, and vague enough that most people never work out where theirs is coming from. The word covers at least five different physiological states, from a straightforward calorie shortfall to iron deficiency that has been building for months, and each one responds to a different correction. Treating them as one problem is why so much advice on the subject amounts to "it passes."
What follows covers how often fatigue was reported in the trials, when it starts and when it fades, why the energy deficit is the largest single contributor, why low blood glucose is usually not, how lean mass loss and protein intake fit in, what the hydration literature shows, and where a smaller dose sits in all of it. It also separates what the trials measured from what is being inferred, because on this topic the two are frequently confused.
Key takeaways
- •The Wegovy prescribing information reports fatigue in about 11 percent of adults on semaglutide 2.4 mg versus about 5 percent on placebo, and the Zepbound label reports roughly 5 to 7 percent on tirzepatide versus about 3 percent on placebo.
- •Fatigue in the trials clustered around dose escalation, appearing within one to two weeks of a step up and easing over four to eight weeks at a stable dose.
- •Friedrichsen and colleagues reported in 2021 that semaglutide 2.4 mg reduced ad libitum energy intake by about 35 percent, and a deficit of that size arriving within weeks is the largest single driver of tiredness.
- •Low blood glucose is an uncommon cause of GLP-1 fatigue unless insulin or a sulfonylurea is also prescribed, because the insulin effect of these drugs is glucose dependent.
- •In the STEP 1 body composition substudy, lean mass fell by about 5.3 kg alongside a fat mass loss of about 8.4 kg, so roughly 40 percent of the weight lost was not fat.
- •No trial has compared fatigue across GLP-1 dose levels, so the argument that a microdose produces less of it is mechanistic reasoning rather than a measured result.
How common is fatigue on GLP-1 medications?
Fatigue affects roughly one in nine adults on semaglutide 2.4 mg and about one in fourteen on tirzepatide at the highest dose, with placebo rates of around half that in each case. The Wegovy prescribing information, which pools the STEP 1, 2, and 3 trials, lists fatigue at 11 percent on semaglutide against 5 percent on placebo. The Zepbound prescribing information reports fatigue at approximately 5 percent on 5 mg, 6 percent on 10 mg, and 7 percent on 15 mg of tirzepatide, against approximately 3 percent on placebo.
Those numbers understate the everyday experience for a simple reason. Trial adverse event reporting captures what a participant volunteers or a clinician records as an event, and a person who feels a bit flat for a fortnight after a dose increase frequently does not report it as anything at all. The 11 percent figure represents fatigue someone considered worth mentioning. The proportion who noticed a dip in energy at some point is almost certainly higher, and no trial has measured it with a validated fatigue scale.
The dose gradient in the tirzepatide data is the more useful detail. Fatigue rose step by step from 5 mg to 15 mg, which is the same pattern seen for nausea, vomiting, and diarrhoea across the SURMOUNT-1 arms published by Jastreboff and colleagues in the New England Journal of Medicine in 2022. When an adverse effect scales with dose in this way, the reasonable inference is that a lower dose produces less of it, although that inference has not been tested below the lowest trial dose.
Fatigue reported as an adverse event, percent of participants
Values from the Wegovy prescribing information (pooled STEP 1, 2, and 3) and the Zepbound prescribing information (pooled SURMOUNT trials). Different trials, populations, and durations, so the semaglutide and tirzepatide bars are not a head to head comparison.
Roughly a doubling over placebo in each programme, with a visible dose gradient in the tirzepatide arms.
When does GLP-1 fatigue start, and does it go away?
Fatigue usually begins within one to two weeks of starting or stepping up a dose and eases over four to eight weeks once the dose is held steady. The STEP and SURMOUNT protocols escalated every four weeks, and the adverse event curves in both programmes show the same shape: a rise after each step, a partial settling before the next one, and a decline once the maintenance dose is reached. Wharton and colleagues described this escalation-linked pattern in their 2022 clinical practice recommendations on managing gastrointestinal effects, and fatigue tracks the gastrointestinal effects closely because they share causes.
The timing has a practical implication that is easy to miss. A person whose tiredness appeared in week two and is still present in week ten at the same dose is not experiencing the escalation effect any more. Something else has taken over, and the most common candidates are an energy intake that has stayed too low, a fluid intake that never recovered, protein that fell with everything else, or a nutrient store that has quietly run down. Each of those gets worse with time rather than better, which is the opposite of the drug's acute effect.
A microdose protocol that moves in smaller steps spreads the same escalation over a longer period, which in principle produces lower peaks. Nobody has measured this. The curves below are drawn to show the shape the trial data imply and the shape a slower titration would be expected to produce, and they are labelled as conceptual because that is what they are.
Illustrative proportion reporting fatigue by week, standard titration versus microdose titration
Conceptual curves drawn to reflect the escalation-linked pattern described in the STEP and SURMOUNT adverse event data. These are not measured values from any trial and no study has tracked fatigue week by week on a microdose protocol.
- Standard four-week escalation
- Slower microdose titration
The peak falls between weeks four and eight in the standard pattern. Tiredness that is still climbing at week twelve is unlikely to be the drug.
Why do GLP-1 medications cause fatigue?
The largest single cause is a sudden reduction in energy intake that outpaces the body's ability to adjust. Blundell and colleagues reported in Diabetes, Obesity and Metabolism in 2017 that semaglutide 1.0 mg reduced ad libitum energy intake at a test lunch by about 24 percent compared with placebo. Friedrichsen and colleagues, using the 2.4 mg dose in 2021, found energy intake across a day of test meals roughly 35 percent lower. Applied to a typical starting intake of 2,400 kcal a day, a 35 percent cut removes over 800 kcal daily, which is a deficit most dietary programmes take months to approach and which the medication produces inside a few weeks.
The body responds to a deficit of that size the way it responds to any energy shortage. Rosenbaum and Leibel documented in the International Journal of Obesity in 2010 that resting energy expenditure falls beyond what the loss of tissue predicts, sympathetic nervous system activity drops, thyroid hormone output declines, and spontaneous physical activity decreases. Each of these is an adaptation that conserves fuel, and each of them feels, from the inside, like tiredness. The adaptation is not a malfunction, but it is not pleasant either.
Several smaller contributors sit alongside the deficit. Protein intake usually falls in proportion with everything else, and protein is what maintains the muscle that generates physical capacity. Fluid intake falls because thirst is blunted and because people drink with meals they are no longer eating. Sleep is fragmented by nausea, reflux, or an unfamiliar sensation of emptiness at night. Iron and vitamin B12 stores run down over months when red meat and overall intake drop. Glucose variability is a real but minor contributor for most people, for reasons covered in the next section.
Conceptual contribution of each mechanism to fatigue on a GLP-1 protocol
Illustrative shares intended to show relative importance as described across the trial, energy balance, and hydration literature. These are not measured proportions and no study has partitioned the causes of fatigue this way in an individual person.
The top three bars are all consequences of eating less, which is why a food and fluid log resolves more cases than any blood test.
Is GLP-1 fatigue caused by low blood sugar?
Usually not, when the medication is used on its own. GLP-1 receptor agonists stimulate insulin release in a glucose dependent manner, meaning the effect on insulin secretion is strong when glucose is high and fades as glucose falls toward normal. Nauck and colleagues describe this mechanism in detail in their 2021 review in Molecular Metabolism, and it is the reason these drugs carry a low intrinsic risk of hypoglycaemia despite their potent effect on glycaemia.
The trial data agree. The Wegovy prescribing information reports clinically significant hypoglycaemia in about 6.2 percent of adults with type 2 diabetes on semaglutide 2.4 mg versus about 2.5 percent on placebo in STEP 2, a population in which most participants were also taking other glucose lowering medication. In the STEP 1 population without diabetes, hypoglycaemia was not a meaningful finding. The picture changes completely when insulin or a sulfonylurea is co-prescribed, because those drugs push insulin regardless of glucose and the GLP-1 medication adds to their effect.
What people often mistake for low blood sugar is the sensation of a large deficit. Shakiness, irritability, and a heavy head after skipping meals can occur with a normal glucose reading, because the body signals an energy shortage through more than one channel. A home glucose meter reading during an episode is the fastest way to tell the two apart. A value below 3.9 mmol/L, or 70 mg/dL, is hypoglycaemia and warrants a conversation with the prescriber. A normal reading with the same symptoms points back to the deficit.
Reduction in ad libitum energy intake versus placebo, percent
The Blundell 2017 and Friedrichsen 2021 values are from controlled test meal studies of semaglutide at the doses shown. The microdose value is an illustrative figure and has not been measured in any published study.
The size of the intake reduction, not the glucose level, is what most people are feeling.
How much do lean mass loss and low protein intake contribute?
Around 40 percent of the weight lost on semaglutide 2.4 mg in STEP 1 came from lean mass, and losing lean mass reduces the physical capacity that people experience as energy. In the dual energy X-ray absorptiometry substudy reported by Wilding and colleagues in the New England Journal of Medicine in 2021, fat mass fell by a mean of about 8.4 kg and lean body mass by about 5.3 kg over 68 weeks. Lean mass includes water, organ tissue, and bone as well as muscle, so not all of that 5.3 kg is contractile tissue, but a meaningful share of it is.
This ratio is not unusual for large weight loss. Diet-induced loss without resistance training typically gives up 20 to 30 percent of the total as lean tissue, and larger and faster losses tend toward the upper end. Neeland and colleagues reviewed the lean mass data across GLP-1 based therapies in Diabetes, Obesity and Metabolism in 2024 and reached the same conclusion the older dietary literature had: the proportion tracks the size and speed of the deficit and the adequacy of protein and loading, rather than anything specific to the drug.
Protein is the modifiable part. Wycherley and colleagues pooled 24 trials in the American Journal of Clinical Nutrition in 2012 and found that higher protein intake during energy restriction preserved about 0.4 kg more fat-free mass than standard protein, with greater fat loss alongside. The working range for lean mass preservation during a deficit is 1.2 to 1.6 grams per kilogram of body weight per day, and the arithmetic is where the difficulty starts. A 100 kg adult needs 120 to 160 grams, which is roughly 500 to 700 grams of cooked chicken or the equivalent, eaten by someone whose appetite has dropped by a third. Smaller, more frequent protein-forward meals are the only practical way most people reach it.
Mean body composition change over 68 weeks, STEP 1 DEXA substudy, kg
Semaglutide 2.4 mg arm, from Wilding and colleagues 2021. Substudy of 140 participants.
Roughly 40 percent of the total came from the lean compartment.
Daily protein target range at 1.2 to 1.6 g/kg, grams
Arithmetic applied to the range most often cited for lean mass preservation during energy restriction. Individual needs vary and anyone with kidney disease should follow their clinician's guidance instead.
- 1.2 g/kg
- 1.6 g/kg
Reaching even the lower bar on a suppressed appetite takes deliberate planning.
Can dehydration and low sodium explain GLP-1 fatigue?
Yes, and it is the cause most often fixed within a day or two once it is recognised. Fluid intake on a GLP-1 medication falls for three overlapping reasons: thirst is blunted along with appetite, a large share of daily fluid normally arrives with meals that are now smaller or skipped, and nausea, vomiting, or diarrhoea remove water and sodium directly. Wharton and colleagues flagged fluid intake as a core part of managing gastrointestinal effects in their 2022 recommendations for exactly this reason.
Mild dehydration is enough to produce the symptoms. Ganio and colleagues showed in the British Journal of Nutrition in 2011 that a fluid loss of about 1.5 percent of body mass, which is roughly 1.4 kg in a 95 kg adult, impaired vigilance and working memory and increased fatigue, tension, and anxiety in healthy men. Armstrong and colleagues reported the equivalent finding in women in the Journal of Nutrition in 2012, with mood, concentration, and headache all worse at a similar level of loss. Neither study involved anyone who felt especially thirsty.
Sodium travels with the water. A person who has cut most processed food, eats small meals, and has had a few days of loose stools can run a modest sodium deficit that presents as light-headedness on standing, a dull headache, and a tiredness that noticeably improves after a salty meal. A deliberate two to three litres of fluid a day with some sodium in it, from food, broth, or an electrolyte mix, corrects most of this quickly. Dizziness on standing that does not clear needs a lying and standing blood pressure check, and anyone on a diuretic or blood pressure medication should involve their prescriber, because weight loss often lowers the dose those medications need.
Does a microdose produce less fatigue than a standard dose?
No trial has measured fatigue across GLP-1 dose levels, so any answer is reasoning from mechanism rather than reporting a result. The reasoning runs as follows. Fatigue in the tirzepatide programme scaled with dose. The largest driver of fatigue is the size and speed of the energy intake reduction, and the intake reduction also scales with dose, from about 24 percent at 1.0 mg of semaglutide to about 35 percent at 2.4 mg in the test meal studies. A dose below 1.0 mg would be expected to sit below 24 percent, producing a deficit closer to what conventional dietary programmes aim for and one the body has more time to adapt to.
Each link in that chain has support, and the assembled claim has not been tested. The honest framing is that a smaller dose is expected to produce a smaller deficit, and a smaller deficit is expected to produce less of the tiredness that comes from a deficit. It will do nothing for the tiredness that comes from poor sleep, from a nutrient deficiency, or from a thyroid problem that was there before the protocol began. Those need to be identified on their own terms.
Exercise deserves a mention here because it runs against intuition. Puetz, O'Connor, and Dishman pooled 70 trials in Psychological Bulletin in 2006 and found that regular exercise reduced feelings of fatigue and increased feelings of energy with a moderate effect size, including in people who were tired at baseline. Resistance training in particular addresses the lean mass problem directly. Someone who feels too tired to train is often the person for whom a short session would do the most, provided the food and fluid to support it are in place first.
How should different patterns of fatigue be interpreted?
The timing and character of the tiredness usually point to its cause more reliably than any single test, because the five main causes produce five recognisably different patterns. A tiredness that tracks the injection is a drug effect. A flat daily heaviness with cold hands is a deficit. Light-headedness on standing is fluid and sodium. A shaky, sweaty episode that carbohydrate fixes in ten minutes is glucose, which is rare without other medication. A slow build over months with breathlessness is worth a blood count.
The order of investigation follows the order of likelihood. A three day food and fluid log costs nothing and resolves most cases by showing an intake far below what the person assumed. If the log looks adequate and the tiredness persists beyond two months at a stable dose, the standard bloods a clinician will consider are a full blood count, ferritin, vitamin B12, thyroid function, and a basic metabolic panel. Anyone already on insulin, a sulfonylurea, a diuretic, or blood pressure medication should involve their prescriber earlier rather than later, since weight loss changes what those doses need to be.
| Pattern | What it usually points to | Practical approach |
|---|---|---|
| Worst in the first two hours after the injection, then clears | Acute drug effect, often with mild nausea | Timing the injection to the evening moves the trough into sleep. This pattern is dose related, tends to fade within four to six weeks at a stable dose, and rarely needs anything beyond patience and a review of whether the last step up was too large. |
| Flat, heavy tiredness every day with cold hands and low motivation | Energy deficit larger than intended, possibly with under-eating protein | A three day food log usually shows intake far below what the person believes. Restoring a floor of roughly 1.2 g/kg of protein and adding a modest amount of energy back tends to lift this within a week or two. If it does not, a clinician should look at thyroid function and iron. |
| Light-headed when standing, headache, tiredness that improves with a salty meal | Low fluid and sodium intake, sometimes with diarrhoea or vomiting | Thirst is blunted on GLP-1 medications, and fluid intake often falls alongside food. Two to three litres of fluid a day with some sodium in it corrects most of this quickly. Persistent dizziness on standing needs a blood pressure check lying and standing. |
| Shaky, sweaty, hungry tiredness that resolves fast with carbohydrate | Low glucose, which is uncommon unless insulin or a sulfonylurea is also prescribed | GLP-1 receptor agonists on their own rarely cause hypoglycaemia because their insulin effect is glucose dependent. Anyone on insulin or a sulfonylurea should have those doses reviewed by the prescriber, and a home glucose reading during an episode settles the question. |
| Tiredness that builds over months alongside breathlessness on stairs | Possible iron deficiency, B12 shortfall, or anaemia | Reduced red meat, reduced overall intake, and menstrual losses combine over months rather than weeks. A full blood count, ferritin, and B12 are the tests a clinician will usually order, and correcting a real deficiency resolves this in a way that no food log adjustment will. |
1.5%
Body mass fluid loss that impaired mood and increased fatigue in the Ganio 2011 and Armstrong 2012 studies
1.2 to 1.6
Grams of protein per kilogram per day, the working range for lean mass preservation during a deficit
0
Trials comparing fatigue or energy outcomes across GLP-1 dose levels
The tiredness is information, not a verdict
Most fatigue on a GLP-1 protocol is the body reporting that fuel, fluid, or protein arrived in smaller quantities than it was ready for, and it responds to correcting whichever of those is short. The trial data establish that fatigue is roughly twice as common on these medications as on placebo, that it scales with dose, and that it clusters around escalation. The energy balance and hydration literature explain why. What no trial has done is measure whether a smaller, slower dose produces less of it, and that gap should be stated plainly rather than papered over. A tiredness that outlasts the escalation window, or that comes with dizziness, breathlessness, or a glucose reading below 3.9 mmol/L, has stopped being a side effect and become a symptom that a clinician should hear about.
"The drug turned the appetite down. Nobody told the rest of the body, and it is still running on the old fuel schedule. Fatigue is the sound of that mismatch."
Frequently asked questions
How common is fatigue on GLP-1 medications?
Fatigue is a recognised adverse effect of GLP-1 receptor agonists at obesity doses, and the prescribing information puts a number on it. The Wegovy label reports fatigue in about 11 percent of adults on semaglutide 2.4 mg compared with about 5 percent on placebo across the pooled STEP trials. The Zepbound label reports fatigue in roughly 5 to 7 percent of adults on tirzepatide, depending on dose, against about 3 percent on placebo. Most of the excess is mild to moderate and concentrated in the first weeks of each dose step.
Why do GLP-1 medications make people tired?
The main driver is a sudden and large reduction in energy intake, with the drug's direct effects layered on top. Friedrichsen and colleagues reported in 2021 that semaglutide 2.4 mg lowered ad libitum energy intake by about 35 percent, and a deficit of that size arriving within weeks is something the body registers as low fuel. Reduced fluid and sodium intake, reduced protein, disrupted sleep from nausea or reflux, and the acute effect of the drug in the hours after an injection each contribute a smaller share. Low blood glucose is not usually the cause unless insulin or a sulfonylurea is also prescribed.
When does GLP-1 fatigue start, and how long does it last?
Fatigue usually appears in the first one to two weeks after starting or stepping up a dose and eases within four to eight weeks at a stable dose. Adverse effects in the STEP and SURMOUNT trials clustered around dose escalation, and fatigue follows the same shape. Tiredness that persists beyond two months at a steady dose, or that gets worse rather than better, is less likely to be a drug effect and more likely to reflect under-eating, dehydration, poor sleep, or a nutrient deficiency that has had time to develop.
Is GLP-1 fatigue caused by low blood sugar?
Rarely, when the medication is used on its own. GLP-1 receptor agonists increase insulin release only when glucose is elevated, so they do not typically push glucose into the hypoglycaemic range by themselves. The Wegovy label reports clinically significant hypoglycaemia in about 6 percent of people with type 2 diabetes on semaglutide versus about 2.5 percent on placebo, and that population was largely on other glucose lowering drugs. Anyone taking insulin or a sulfonylurea alongside a GLP-1 medication is in a different position and should have those doses reviewed by the prescriber.
How much lean mass is lost on a GLP-1 medication, and does that affect energy?
In the STEP 1 body composition substudy, roughly 40 percent of the weight lost on semaglutide 2.4 mg came from lean mass, with fat mass falling by about 8.4 kg and lean mass by about 5.3 kg over 68 weeks. That ratio is similar to what is seen with other forms of substantial weight loss and includes water and organ tissue as well as muscle. Losing muscle reduces strength and the capacity to do work, which people experience as tiredness during ordinary activity. Adequate protein intake and resistance training are the two interventions with evidence for protecting lean mass during a deficit.
How much protein should someone on a GLP-1 protocol eat to reduce fatigue?
A working target of 1.2 to 1.6 grams of protein per kilogram of body weight per day is the range most often cited for preserving lean mass during energy restriction. For a 100 kg adult that is 120 to 160 grams a day, which is difficult to reach when appetite is suppressed and meals are small. Wycherley and colleagues showed in a 2012 meta-analysis that higher protein during energy restriction preserved more fat-free mass than standard protein. Spreading protein across three or four smaller meals is easier on a reduced appetite than trying to fit it into two.
Can dehydration cause fatigue on a GLP-1 protocol?
Yes, and it is one of the more easily corrected causes. Thirst is blunted on GLP-1 receptor agonists, people drink less because they eat less, and nausea, vomiting, or diarrhoea remove fluid and sodium directly. Ganio and colleagues showed in 2011 that even mild dehydration of around 1.5 percent of body mass impaired mood and produced fatigue and headache in healthy men, and Armstrong and colleagues found the same in women in 2012. A deliberate fluid intake of two to three litres a day, with some sodium, corrects most of this within a day or two.
Does microdosing produce less fatigue than a standard GLP-1 dose?
No trial has measured fatigue across GLP-1 dose levels, so the claim rests on reasoning rather than a result. The mechanistic case is that fatigue in the trials was dose related and clustered around escalation, that a smaller dose produces a smaller and more gradual reduction in energy intake, and that a smaller deficit puts less strain on the systems that generate tiredness. Each of those links has support, but the assembled claim has not been tested, and anyone presenting it as an established finding is overstating the evidence.
Clinical references
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
- Novo Nordisk. Wegovy (semaglutide) injection 2.4 mg: prescribing information. US Food and Drug Administration; 2021, with subsequent revisions.
- Eli Lilly and Company. Zepbound (tirzepatide) injection: prescribing information. US Food and Drug Administration; 2023, with subsequent revisions.
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017;19(9):1242-1251.
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021;23(3):754-762.
- Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. International Journal of Obesity. 2010;34(Suppl 1):S47-S55.
- Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after The Biggest Loser competition. Obesity. 2016;24(8):1612-1619.
- Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition. 2012;96(6):1281-1298.
- Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. American Journal of Clinical Nutrition. 2015;101(6):1320S-1329S.
- Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024;26(Suppl 4):16-27.
- Ganio MS, Armstrong LE, Casa DJ, et al. Mild dehydration impairs cognitive performance and mood of men. British Journal of Nutrition. 2011;106(10):1535-1543.
- Armstrong LE, Ganio MS, Casa DJ, et al. Mild dehydration affects mood in healthy young women. Journal of Nutrition. 2012;142(2):382-388.
- Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine. 2022;134(1):14-19.
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021;46:101102.
- Puetz TW, O'Connor PJ, Dishman RK. Effects of chronic exercise on feelings of energy and fatigue: a quantitative synthesis. Psychological Bulletin. 2006;132(6):866-876.
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and is not a substitute for the prescriber or clinician responsible for your care. Nothing here describes a treatment for fatigue, anaemia, thyroid disease, hypoglycaemia, obesity, type 2 diabetes, or any other condition, and no GLP-1 receptor agonist is approved for the treatment of fatigue. GLP-1 microdosing is an off label approach, no trial has compared fatigue or energy outcomes across GLP-1 dose levels, and several charts in this article contain illustrative, conceptual, or approximated values, labelled as such, which should not be read as measured results or as targets. Do not start, stop, or change the dose of insulin, a sulfonylurea, a diuretic, a blood pressure medication, or any other medication on the basis of this article. Persistent fatigue, fainting, chest pain, breathlessness, confusion, or a blood glucose reading below 3.9 mmol/L requires prompt medical review.